Bosentan and Buprenorphine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Bosentan
No brand names on recordBuprenorphine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Let's talk about taking bosentan (a blood pressure medicine for the lungs) together with buprenorphine (used for pain or for opioid dependence). Bosentan can speed up how your body breaks down buprenorphine, so there ends up being less buprenorphine in your system. That can make it work less well, and you might feel opioid withdrawal symptoms like sweating, chills, aches, nausea, or restlessness.
The good news is your care team can handle this. Please don't stop or change either medicine on your own. Just let your pharmacist or doctor know you take both. They can adjust your buprenorphine dose and keep a closer eye on how you're feeling so you stay comfortable and stable.
Effect: Bosentan is a moderate CYP3A4 inducer; it induces CYP3A4-mediated metabolism of buprenorphine, lowering buprenorphine plasma concentrations (reduced AUC/Cmax) and reducing efficacy. Neither drug is a prodrug here; this is a straightforward induction (reduced-effect) interaction.
Direction: reduced buprenorphine exposure, risk of opioid withdrawal.
Evidence: probable. Onset: unspecified (expect over days as induction develops).
Management:
- If bosentan is added, titrate buprenorphine upward to stable effect and monitor for withdrawal.
- On bosentan discontinuation, consider a buprenorphine dose reduction and monitor for respiratory depression.
- Prefer a formulation allowing precise titration; for subQ depot products, confirm adequacy of plasma levels.
What happens
Reduced buprenorphine exposure and reduced efficacy of buprenorphine
Interaction Deep Dive
Taking buprenorphine together with a CYP3A4 inducer can lower plasma buprenorphine concentrations, potentially triggering symptoms of opioid withdrawal. When a patient on buprenorphine requires a CYP3A4 inducer, it may be appropriate to raise the buprenorphine dose until stable drug effects are reached, with monitoring for withdrawal. Conversely, if a CYP3A4 inducer is stopped in a patient receiving buprenorphine, consider lowering the buprenorphine dose and watching for respiratory depression2. Should dose adjustment not be feasible once the CYP3A4 inducer is no longer present, switch the patient back to a buprenorphine formulation that allows finer dose titration. For patients moving from transmucosal buprenorphine given alongside CYP3A4 inducers, confirm through monitoring that the plasma buprenorphine level delivered by subQ buprenorphine is sufficient. Among patients already established on subQ buprenorphine who need a CYP3A4 inducer, monitor for withdrawal. When the buprenorphine dose proves inadequate while the concomitant drug is present, and that drug cannot be reduced or stopped, modify the buprenorphine dose. If the available doses cannot reach the target dose, treat the patient with a buprenorphine formulation that permits more precise dose adjustments1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
Keep taking both medicines as prescribed unless your care team tells you otherwise. The main thing to watch for is opioid withdrawal (aches, chills, sweating, stomach upset, restlessness, feeling anxious), which can signal your buprenorphine isn't working as strongly.
Here's what your team typically does:
- They may adjust and individualize your buprenorphine dose while bosentan is on board, and monitor you more closely.
- If bosentan is later stopped, they may lower your buprenorphine dose and watch for slowed breathing.
- They may use a buprenorphine form that allows more precise dose changes.
Tell your pharmacist or prescriber that you take both, and report any withdrawal symptoms.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) Studies have not examined how a concurrently administered CYP3A4 inducer affects buprenorphine exposure in patients receiving subQ buprenorphine; nevertheless, these interactions have been demonstrated in investigations involving transmucosal buprenorphine. Buprenorphine's effects may depend on the route by which it is administered 1.
Common questions
Can I take Bosentan and Buprenorphine together?
Bosentan can lower buprenorphine levels and trigger opioid withdrawal, so tell your care team you take both; they can adjust your buprenorphine dose and monitor you to keep you stable. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Bosentan and Buprenorphine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Bosentan and Buprenorphine interaction managed?
Keep taking both medicines as prescribed unless your care team tells you otherwise. The main thing to watch for is opioid withdrawal (aches, chills, sweating, stomach upset, restlessness, feeling anxious), which can signal your buprenorphine isn't working as strongly. Here's what your team typically does: They may adjust and individualize your buprenorphine dose while bosentan is on board, and mon… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Bosentan or Buprenorphine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Keep reading about Bosentan
Keep reading about Buprenorphine
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist